Furthermore in NPC, treatment with soluble LIFR, an antagonist of LIF or rapamycin, an mTOR inhibitor of LIF, was found to reduce cell survival and tumour growth following irradiation in-vitro and in-vivo [22]. Here, LIF is linked to nasopharyngeal carcinoma.